

| | | | | | | | |
|--|--|--|--|--|--|---|--|
| INFORMATION DISCLOSURE CITATION <i>(Use several sheets if necessary)</i> | | | | Docket Number (Optional) F03-354-USDiv | | Application Number 10/634,836 | |
| | | | | Applicant(s) Hisaki KATO, et al. | | | |
| | | | | Filing Date August 6, 2003 | | Group Art Unit 2822 1656 | |

| U.S. PATENT DOCUMENTS | | | | | | | |
|-----------------------|-----|-----------------|------|------|-------|----------|-------------------------------|
| *EXAMINER INITIAL | REF | DOCUMENT NUMBER | DATE | NAME | CLASS | SUBCLASS | FILING DATE IF APPROPRIATE |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |

| U.S. PATENT APPLICATION PUBLICATIONS | | | | | | | |
|--------------------------------------|-----|-----------------|------|------|-------|----------|-------------------------------|
| *EXAMINER INITIAL | REF | DOCUMENT NUMBER | DATE | NAME | CLASS | SUBCLASS | FILING DATE IF APPROPRIATE |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |

| FOREIGN PATENT DOCUMENTS | | | | | | | | |
|--------------------------|-----|-----------------|----------|---------|-------|----------|-------------|----|
| | REF | DOCUMENT NUMBER | DATE | COUNTRY | CLASS | SUBCLASS | Translation | |
| | | | | | | | YES | NO |
| CMK | | H7-7182 | 01/10/99 | Japan | | | ABS | |
| | | | | | | | | |
| | | | | | | | | |
| | | | | | | | | |
| | | | | | | | | |

| OTHER DOCUMENTS | | | (Including Author, Title, Date, Pertinent Pages, Etc.) |
|-----------------|--|--|--|
| CMK | | Japanese Office Action, dated May 24, 2005, with partial English translation | |
| CMK | | NAKAMURA, et al., "Ridge-geometry InGaN multi-quantum-well-structure laser diodes", APPLIED PHYSICS LETTERS, September 2, 1996, Vol. 69, No. 10, pp. 1477-1479 | |

| | |
|--------------|------------------------------------|
| EXAMINER | DATE CONSIDERED 11/10/05 |
|--------------|------------------------------------|

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP Section 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



PTO/SB/08A (08-03)
Approved for use through 07/31/2008. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.



| | | | | | |
|--|---|----|---|--------------------------|---------------------------|
| Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary) | | | | Complete if Known | |
| | | | | Application Number | 10/643,836 |
| | | | | Filing Date | August 18, 2003 |
| | | | | First Named Inventor | J.-B. Dumas Milne Edwards |
| | | | | Art Unit | |
| | | | | Examiner Name | |
| Sheet | 1 | of | 6 | Attorney Docket Number | G-078US05DIV |

| U.S. PATENT DOCUMENTS | | | | | |
|-----------------------|-----------------------|---|--------------------------------|--|---|
| Examiner Initials* | Cite No. ¹ | Document Number Number - Kind Code ² (if known) | Publication Date MM-DD-YYYY | Name of Patentee or Applicant of Cited Document | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear |
| CMK | U1 | US-4,914,025 | 04/03/1990 | Manoil <i>et al.</i> | All |
| | U2 | US-5,536,637 | 07/16/1996 | Jacobs | All |
| | U3 | US-5,019,369 | 05/28/1991 | Presant <i>et al.</i> | All |
| | U4 | US-5,872,141 | 02/16/1999 | Umbriet <i>et al.</i> | All |
| | U5 | US-6,034,062 | 03/07/2000 | Thies <i>et al.</i> | All |
| | U6 | US-6,204,060 | 03/20/2001 | Mehtali <i>et al.</i> | All |
| | U7 | US-6,110,490 | 08/29/2000 | Theirry | All |
| CMK | U8 | US-6,242,179 | 06/05/2001 | Shah <i>et al.</i> | All |
| | U9 | US- | | | |

| FOREIGN PATENT DOCUMENTS | | | | | | | |
|--------------------------|--------------------------|---------------------------|---|--------------------------------|--|---|-----|
| Examiner Initials* | Cite No. ¹ | Foreign Patent Document | | Publication Date MM-DD-YYYY | Name of Patentee or Applicant of Cited Document | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear | T* |
| | | Country Code ³ | - Number ⁴ - Kind Code ⁵ (if known) | | | | |
| CMK | F1 | EP 1130094 A2 (CD-ROM) | | 07/07/2000 | Helix Research Institute | All | |
| J | F2 | WO 98/55614 A2 | | 12/10/1998 | Genetics Institute, Inc. | All | |
| | F3 | WO 97/07198 A2 | | 02/27/1997 | Genetics Institute | All | |
| | F4 | WO 97/04097 A2 | | 02/06/1997 | Genetics Institute | All | |
| | CMK | F5 | WO 97/18826 A2 | | 07/13/1995 | Schering Corp. | All |
| | F6 | | | | | | |
| | F7 | | | | | | |

| | | | |
|--------------------|------------|-----------------|----------|
| Examiner Signature | <i>CMK</i> | Date Considered | 11/10/05 |
|--------------------|------------|-----------------|----------|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kind Codes of USPTO Patent Documents at www.uspto.gov or MPEP901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard T.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.


This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9189) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

| | | | | | |
|--|---|----|---|--------------------------|---------------------------|
| Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary) | | | | Complete if Known | |
| | | | | Application Number | 10/643,836 |
| | | | | Filing Date | August 18, 2003 |
| | | | | First Named Inventor | J.-B. Dumas Milne Edwards |
| | | | | Group Art Unit | |
| Examiner Name | | | | | |
| Sheet | 2 | of | 6 | Attorney Docket Number | G-078US05DIV |

| NON PATENT LITERATURE DOCUMENTS | | | | |
|---------------------------------|-----------------------|---|--|----------------|
| Examiner Initials* | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | | T ² |
| CKK | R1 | BOUGUELERET, L. <i>et al.</i> "Extended cDNAs Useful for Expressing Secreted Proteins and to Obtain Specific Antibodies", 2000, pp. 203-204, Accession No. AAY59685. | | |
| | R2 | CAMERON, C. <i>et al.</i> "Function and Protective Capacity of <i>Treponema Pallidum</i> Subsp. <i>Pallidum</i> Glycerophosphodiester Phosphodiesterase", <i>Infection and Immunity</i> , 1998, pp. 5763-5770, Vol. 66, No. 12, American Society for Microbiology. | | |
| | R3 | DOWNES, G. <i>et al.</i> "Structure and Mapping of the G Protein $\gamma 3$ Subunit Gene and a Divergently Transcribed Novel Gene", <i>Gng31g</i> , <i>Genomics</i> , 1998, pp. 220-230, Vol. 53, Academic Press. | | |
| | R4 | INOUE, S. <i>et al.</i> "Growth Suppression of <i>Escherichia coli</i> by Induction of Expression of Mammalian Genes with Transmembrane or ATPase Domains", <i>Biochem. Biosphys. Reas. Comm.</i> , 2000, pp. 553-561, Vol. 268, Academic Press. | | |
| | R5 | JANSON, H. <i>et al.</i> "Protein D, the Glycerophosphodiester Phosphodiesterase from <i>Haemophilus influenzae</i> with Affinity for Human Immunoglobulin D, Influences Virulence in a Rat Otitis Model", <i>Infection and Immunity</i> , 1994, pp. 4848-4854, Vol. 62, No. 11, American Society for Microbiology. | | |
| | R6 | LARSON, T. <i>et al.</i> "Periplasmic Glycerophosphodiester Phosphodiesterase of <i>Escherichia coli</i> , a New Enzyme of the <i>glp</i> Regulon", <i>J. Biol. Chem.</i> , 1983, pp. 5428-5432, Vol. 258, No. 9. | | |
| | R7 | MAGRÉ, J. <i>et al.</i> "Identification Of The Gene Altered In Berardinelli-Seip Congenital Lipodystrophy On Chromosome 11q13", <i>Nature Genetics</i> , 2001, pp. 365-370, Vol. 28. | | |
| | R8 | MELDRUM, Brian "Glutamate as a Neurotransmitter in the Brain: Review of Physiology and Pathology", <i>The Journal of Nutrition - Supplement</i> (presented at the International Symposium on Glutamate, 1998), 2000, pp. 1007S-1015S, Pub: American Society for Nutritional Sciences. | | |
| | R9 | MUNSON, R. <i>et al.</i> "Protein D, a Putative Immunoglobulin D-Binding Protein Produced by <i>Haemophilus influenzae</i> , Is Glycerophosphodiester Phosphodiesterase", <i>J. Bacteriology</i> , 1993, pp. 4569-4571, Vol. 175, No. 14. | | |
| | R10 | NEER, Eva "Heterotrimeric G Proteins: Organizers of Transmembrane Signals", <i>Cell</i> , 1995, pp. 249-257, Vol. 80, Cell Press. | | |
| | R11 | SCHOEPP, D. <i>et al.</i> "Metabotropic Glutamate Receptors in Brain Function and Pathology", <i>TIPS</i> , 1993, pp. 13-20, Vol. 14, Elsevier Science Publishers, Ltd., UK. | | |
| | R12 | ZHENG, B. <i>et al.</i> "MIR16, a Putative Membrane Glycerophosphodiester Phosphodiesterase, Interacts with RGS16", <i>PNAS</i> , 2000, pp. 3999-4004, Vol. 97, No. 8. | | |
| CKK | R13 | ZHENG, B. <i>et al.</i> "MIR16, a Putative Membrane Glycerophosphodiester Phosphodiesterase, Interacts with RGS16", <i>Proc. Natl. Acad. Sci. U.S.A.</i> , 2000, pp. 3999-4004, Vol. 97, No. 8, Accession No. AAF65234 (bases 1 to 331). | | |

| | | | |
|--------------------|---|-----------------|----------|
| Examiner Signature |  | Date Considered | 11/10/05 |
|--------------------|---|-----------------|----------|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Complete if Known


| | |
|------------------------|---------------------------|
| Application Number | 10/643,836 |
| Filing Date | August 18, 2003 |
| First Named Inventor | J.-B. Dumas Milne Edwards |
| Group Art Unit | |
| Examiner Name | |
| Attorney Docket Number | G-078US05DIV |

| | | | |
|-------|---|----|---|
| Sheet | 3 | of | 6 |
|-------|---|----|---|

NON PATENT LITERATURE DOCUMENTS

| Examiner Initials* | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ² |
|--------------------|-----------------------|--|----------------|
| CMK | R14 | ZHENG, B. <i>et al.</i> "MIR16, a Putative Membrane Glycerophosphodiester Phosphodiesterase, Interacts with RGS16", <i>Proc. Natl. Acad. Sci. U.S.A.</i> , 2000, pp. 3999-4004, Vol. 97, No. 8, Accession No. AF212862 (bases 1 to 1200). | |
| | R15 | Glycerophosphoryl Diester Phosphodiesterase <i>Escherichia coli</i> , 1989, NiceProt View of SWISS-PROT: P10908. | |
| | R16 | Glycerophosphoryl Diester Phosphodiesterase, periplasmic (Precursor) <i>Escherichia coli</i> , 1991, NiceProt View of SWISS-PROT: P09394. | |
| | R17 | Glycerophosphoryl Diester Phosphodiesterase [Precursor] <i>Haemophilus influenzae</i> , 1995, NiceProt View of SWISS-PROT: Q06282. | |
| | R18 | Similar to G Protein Gamma 3 Linked Gene <i>Homo Sapiens</i> , 2001, NiceProt View of SWISS-PROT: Q9BSQ0. | |
| | R19 | Hypothetical 43.1 kDa protein <i>Mus musculus</i> , 2000, NiceProt View of SWISS-PROT: Q9JMF1. | |
| | R20 | BORK, P. "Powers and Pitfalls in Sequence Analysis: The 70% Hurdle", <i>Genome Research</i> , 2000, pp. 398-400, Vol. 10. | |
| | R21 | BROUN, P. <i>et al.</i> , "Catalytic Plasticity of Fatty Acid Modification Enzymes Underlying Chemical Diversity of Plant Lipids", <i>Science</i> , 1998, pp. 1315-1317, Vol. 282. | |
| | R22 | SEFFERNICK, J.L. <i>et al.</i> , "Melamine Deaminase and Atrazine Chlorohydrolase: 98 Percent Identical but Functionally Different", <i>Journal of Bacteriology</i> , 2001, pp. 2405-2410, Vol. 183, No. 8, American Society for Microbiology. | |
| | R23 | VAN DE LOO, F. J. <i>et al.</i> , "An Oleate 12-hydroxylase from <i>Ricinus Communis</i> L. is a Fatty Acyl Desaturase Homolog", <i>Proc. Natl. Acad. Sci. USA</i> , 1995, pp. 6743-6747, Vol. 92. | |
| | R24 | WITKOWSKI, A. <i>et al.</i> , "Conversion of β -Ketoacyl Synthase to a Malonyl Decarboxylase by Replacement of the Active-Site Cysteine with Glutamine", <i>Biochemistry</i> , 1999, pp. 11643-11650, Vol. 38. | |
| | R25 | ATTWOOD, T. "Genomics: The Babel of Bioinformatics", <i>Science</i> , 2000, pp. 471-473, Vol. 290, No. 5491. | |
| CMK | R26 | RUBEN S.M. <i>et al.</i> "Human Secreted Protein Encoded by Gene 21", <i>Database Geneseq</i> [online], March 23, 2000, AC No. Y76144, XP002163702. | |

Examiner Signature



Date Considered

11/10/05

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Approved for use through 07/31/2008. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

PTO/SB/08B (08-03)



| | | | |
|--|---|--------------------------|---------------------------|
| Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary) | | Complete if Known | |
| | | Application Number | 10/643,836 |
| | | Filing Date | August 18, 2003 |
| | | First Named Inventor | J.-B. Dumas Milne Edwards |
| | | Group Art Unit | |
| | | Examiner Name | |
| Sheet | 4 | of | 6 |
| | | Attorney Docket Number | G-078US05DIV |

| NON PATENT LITERATURE DOCUMENTS | | | |
|---------------------------------|----------|--|----------------|
| Examiner Initials* | Cite No. | Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ² |
| CNK | R27 | RUBEN S.M. <i>et al.</i> "Human Secreted Protein Encoded by Gene 21", <i>Database Geneseq</i> [online], March 23, 2000, AC No. Z65270, XP002163703. | |
| | R28 | DATABASE EMBL[online], AC No. AI911546, July 30, 1999, Natl. Cancer Inst., "ty73d05.x1 NCI_CGAP_Kid11 Homo Sapiens cDNA Clone IMAGE: 2284713", XP002163704. | |
| | R29 | DATABASE EMBL[online], AC No. AI361251, January 7, 1999, Natl. Cancer Inst., "qy42e02.x1 NCI_CGAP_Bm23 Homo Sapiens cDNA Clone IMAGE: 2014682", XP002163705. | |
| | R30 | JACOBS, K.A. <i>et al.</i> "A Genetic Selection for Isolating cDNAs Encoding Secreted Proteins", <i>Gene, NL, Elsevier</i> , October 1987, pp. 289-296, Vol. 198, Biomedical Press, Amsterdam, XP002045919. | |
| | R31 | TASHIRO, K. <i>et al.</i> "Signal Sequence Trap: A Cloning Strategy for Secreted Proteins and Type I Membrane Proteins", <i>Science</i> , July 30, 1993, pp. 600-603, Vol. 261, American Association for the Advancement of Science, XP000673204. | |
| | R32 | LIM, E.M. <i>et al.</i> "Identification of Mycobacterium Tuberculosis DNA Sequences Encoding Exported Proteins by Using phoA Gene Fusions", <i>Journal of Bacteriology</i> , January 1995, pp. 59-650021-9193/95, Vol. 177, No. 1. | |
| | R33 | MIYAKE <i>et al.</i> "RP105, a Novel B Cell Surface Molecule Implicated in B Cell Activation, is a Member of the Leucine-Rich Repeat Protein Family", <i>The Journal of Immunology</i> , pp. 3333-3340, The American Association of Immunologists, 0022-1767/95. | |
| | R34 | JACOBS <i>et al.</i> "A Novel Method for Isolating Eukaryotic cDNA Clones Encoding Secreted Proteins", <i>Dendritic Cells: Antigen Presenting Cells of T and B Lymphocytes</i> , March 10-16, 1995, C1-207. | |
| | R35 | FUJIWARA, T. <i>et al.</i> "HUM309B01B Clontech Human Aorta PolyA+ mRNA (#6572) Homo Sapiens cDNA Clone GEN-309B01 5', mRNA Sequence", XP002032351, Accession No. D62634. | |
| | R36 | MARRA, M. <i>et al.</i> "The WashU-HHMI Mouse EST Project", XP002032348, Accession No. W08383. | |
| | R37 | MARRA, M. <i>et al.</i> "The WashU-HHMI Mouse EST Project", XP002032350, Accession No. W11170. | |
| | R38 | MARRA, M. <i>et al.</i> "The WashU-HHMI Mouse EST Project", XP002032349, Accession No. W17930. | |
| CNK | R39 | MARRA, M. <i>et al.</i> "The Wash U-HHMI Mouse EST Project", XP002032347, Accession No. W67046. | |

| | | | |
|--------------------|--|-----------------|----------|
| Examiner Signature | | Date Considered | 11/10/05 |
|--------------------|--|-----------------|----------|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.


If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

| | | | |
|--|---|--------------------------|---------------------------|
| Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary) | | Complete If Known | |
| | | Application Number | 10/643,836 |
| | | Filing Date | August 18, 2003 |
| | | First Named Inventor | J.-B. Dumas Milne Edwards |
| | | Group Art Unit | |
| | | Examiner Name | |
| Sheet | 5 | of | 6 |
| | | Attorney Docket Number | G-078US05DIV |

| NON PATENT LITERATURE DOCUMENTS | | | |
|---------------------------------|-----------------------|--|----------------|
| Examiner Initials* | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ² |
| CJK | R40 | ABRAHAM, E., et al., "Phosphatidic Acid Signaling Mediates Lung Cytokine Expression and Lung Inflammatory Injury After Hemorrhage in Mice", <i>J. Exp. Med.</i> , 1995, pp. 569-575, Vol. 181. | |
| | R41 | BRINDLEY, D. and WAGGONER, D. "Phosphatidate Phosphohydrolase And Signal Transduction", <i>Chem. Phys. Lipids</i> , 1996, pp. 45-57, Vol. 80. | |
| | R42 | BURSTEN, S., et al., "Potential Role for Phosphatidic Acid in Mediating the Inflammatory Responses to TNF α and IL-1 β ", <i>Circ. Shock</i> , 1994, pp. 14-29, Vol. 44. | |
| | R43 | ENGLISH, D., "Phosphatidic Acid: A Lipid Messenger Involved in Intracellular and Extracellular Signalling", <i>Cell. Signal.</i> , 1996, pp. 341-347, Vol. 8, No. 5. | |
| | R44 | ENGLISH, D., et al., "Messenger Functions Of Phosphatidic Acid", <i>Chem. Phys. Lipids</i> , 1996, pp. 117-132, Vol. 80. | |
| | R45 | KENT, C. "Eukaryotic Phospholipid Biosynthesis", <i>Ann. Rev. Biochem.</i> , 1995, pp. 315-343, Vol. 64. | |
| | R46 | LEUNG, D., et al., "CT-2576, An Inhibitor Of Phospholipids Signaling, Suppresses Constitutive And Induced Expression Of Human Immunodeficiency Virus", <i>Proc. Natl. Acad. Sci. USA</i> , 1995, pp. 4813-4817, Vol. 92. | |
| | R47 | RICE, G., et al., "Protection From Endotoxic Shock In Mice By Pharmacologic Inhibition Of Phosphatidic Acid", <i>Proc. Natl. Acad. Sci. USA</i> , 1994, pp. 3857-3861, Vol. 91. | |
| | R48 | ROBERTS, R. and MORRIS, A. "Role Of Phosphatidic Acid Phosphatase 2a In Uptake Of Extracellular Lipid Phosphate Mediators", <i>Biochimica et Biophysica Acta</i> , 2000, pp. 33-49, Vol. 1487. | |
| | R49 | SALVADOR, G.A., et al., "Differential Modulation Of Phospholipase D And Phosphatidate Phosphohydrolase During Aging In Rat Cerebral Cortex Synaptosomes", <i>Exp. Gerontology</i> , 2002, pp. 543-552, Vol. 37. | |
| | R50 | STUKEY, J. and CARMAN, G. "Identification Of A Novel Phosphatase Sequence Motif", <i>Protein Science</i> , 1997, pp. 469-472, Vol. 6. | |
| | R51 | Database GENBANK, Accession NP_003702; PANDEY, A.V., et al., "Protein Phosphatase 2A And Phosphoprotein Set Regulate Androgen Production By p450c17", <i>J. Biol. Chem.</i> , 2003, pp. 2837-2844, Vol. 278, Issue 5. | |
| CJK | R52 | Database GENBANK, Accession No. NP_795714; PANDEY, A.V., et al., "Protein Phosphatase 2A And Phosphoprotein SET Regulate Androgen Production By P450c17", <i>J. Biol. Chem.</i> , 2003, pp. 2837-2844, Vol. 278, Issue 5. | |

| | | | |
|--------------------|---|-----------------|----------|
| Examiner Signature |  | Date Considered | 11/10/05 |
|--------------------|---|-----------------|----------|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.


If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.



| | | | |
|--|---|--------------------------|---------------------------|
| Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary) | | Complete if Known | |
| | | Application Number | 10/643,836 |
| | | Filing Date | August 18, 2003 |
| | | First Named Inventor | J.-B. Dumas Milne Edwards |
| | | Group Art Unit | |
| | | Examiner Name | |
| Sheet | 6 | of | 6 |
| | | Attorney Docket Number | G-078US05DIV |

| NON PATENT LITERATURE DOCUMENTS | | | |
|---------------------------------|-----------------------|--|----------------|
| Examiner Initials* | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ² |
| CHK | R53 | Database GENBANK, Accession No. NP_803133; ISHIKAWA, T., et al., "Cell Surface Activities Of The Human Type 2b Phosphatidic Acid Phosphatase", J. Biochem., 2000, pp. 645-651, Volume 127, Issue 4. | |
| | R54 | Database GENBANK, Accession No. NP_808211; ZHANG, N., et al., "Mice Mutant For Ppap2c, A Homolog Of The Germ Cell Migration Regulator Wunen, Are Viable And Fertile", Genesis, 2000, pp. 137-140, Volume 27, Issue 4. | |
| CHK | R55 | Accession No. AAB70690, Human hDPP protein sequence SEQ ID NO:7, May 17, 2001. | |
| | R56 | | |
| | R57 | | |
| | R58 | | |
| | R59 | | |
| | R60 | | |
| | R61 | | |
| | R62 | | |
| | R63 | | |
| | R64 | | |
| | R65 | | |

| | | | |
|--------------------|---|-----------------|----------|
| Examiner Signature |  | Date Considered | 11/10/05 |
|--------------------|---|-----------------|----------|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

